Rate of Progression in Familial Alzheimer's Disease

Swearer, Joan M.; O’Donnell, Brian F.; Ingram, Susan M.; Drachman, David A.

doi:10.1177/089198879600900104

Cited by 26 publications

(6 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…0.07 – 0.11), consistent with common observation of familial AD progressing faster than sporadic AD. 20 Of note, C.I. for acceleration is much tighter (about ten times smaller) in our study versus Chan et al, suggesting greater precision of volumetry estimated from CT than from MR images.…”

Section: Discussioncontrasting

confidence: 52%

Accelerated Brain Atrophy on Serial Computed Tomography

Zahid

Mikheev

Srivatsa

et al. 2016

Journal of Computer Assisted Tomography

View full text Add to dashboard Cite

Objective To validate CT-based longitudinal markers of the progression of Alzheimer's disease (AD). Materials and Methods We retrospectively studied 33 AD patients and 39 non-demented patients with other neurological illnesses (Non-AD) having 4–12 CT exams of the head, over 3.9 ± 1.7 years. At each time point we applied an automatic software to measure whole brain, CSF, and intracranial space (ICS) volumes. Longitudinal measures were then related to disease status and time since first scan using hierarchical models. Results Absolute brain volume loss accelerated for non-AD patients by 0.86 ml/yr2 (95%C.I. 0.64 to 1.08 ml/yr2) and 1.5× faster, i.e. 1.32 ml/yr2 (95%C.I. 1.09 to 1.56 ml/yr2) for AD patients (p= 0.006). In terms of brain volume normalized to ICS, the acceleration in atrophy rate for non-AD patients was 0.0578%/yr2 (95%C.I. 0.0389%/yr2 to 0.0767%/yr2) again, 1.5× faster, i.e. 0.0919%/yr2 (95% C.I. 0.0716%/yr2 to 0.1122%/yr2) for AD patients (p= 0.017). This translates to an increase in atrophy rate from 0.5% to 1.4% in AD versus to 1.1% in non-AD group after 10 years. Conclusion Brain volumetry on CT reliably detected accelerated volume loss in AD and significantly lower acceleration factor in age-matched non-AD patients, leading to the possibility of its use to monitor the progression of cognitive decline and dementia.

show abstract

Section: Discussioncontrasting

confidence: 52%

Accelerated Brain Atrophy on Serial Computed Tomography

Zahid

Mikheev

Srivatsa

et al. 2016

Journal of Computer Assisted Tomography

View full text Add to dashboard Cite

show abstract

“…Future studies dealing exclusively with AD or vascular cases should be pursued, but a more detailed breakdown of AD might be required. It is now accepted that there are several subtypes of AD (Mayeux, Stem & Spaton, 1985), with different deterioration patterns (Hogan, Thierer, Ebly & Parhad, 1994;Swearer, O'Donnell, Ingram & Drachman, 1996).…”

Section: Discussionmentioning

confidence: 99%

Institutionalization in Cognitively-Impaired Older Individuals

Molloy

Bédard

Pedlar

et al. 1999

Clinical Gerontologist

View full text Add to dashboard Cite

Older adults with cognitive impairment are often institutionalized. Many cross-sectional studies have identified factors associated with this outcome but there is a paucity of longitudinal studies examining if progression of the condition is associated with institutionalization. In this study we followed 30 older adults with cognitive impairment for an average of three years. One third of these individuals were institutionalized by the end of the follow up period. The only factor significantly associated with institutionalization was the relationship of the caregivers to the care recipients. Individuals cared for by non-spousal caregivers were more likely to be institutionalized and also more likely to be institutionalized earlier than individuals cared for by their spouses. These results suggest that social factors are more important determinants of institutionalization than the functional status of the care recipients. A better understanding of these social factors is re-

show abstract

“…4 These predictors fall into four broad categories: demographic variables, 5-8 genetic influences, [9][10][11][12][13][14][15] prominent features at time of diagnosis, [16][17][18][19][20] and comorbidities. [21][22][23] Further, progression may be measured in terms of various endpoints.…”

mentioning

confidence: 99%